Ambit Biosciences has secured Astellas Pharma as a strategic partner for its lead product, AC220, which is in Phase II studies in relapsed/refractory acute myeloid leukaemia (AML). Under the agreement, Astellas will jointly develop and commercialise other FMS-like tyrosine kinase-3 (FLT3) inhibitors with the privately owned San Diego-based biotech firm.
Ambit Biosciences has secured Astellas Pharma as a strategic partner for its lead product, AC220, which is in Phase II studies in relapsed/refractory acute myeloid leukaemia (AML). Under the agreement, Astellas will jointly develop and commercialise other FMS-like tyrosine kinase-3 (FLT3) inhibitors with the privately owned San Diego-based biotech firm.
Ambit will receive $40 million up front, and stands to receive up to $350 million in pre-commercialisation payments. It will...
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
